Jacob Plieth writes for Evaluate about AstraZeneca’s effort to not give up on its first-line treatment of metastatic non-small cell lung cancer with immunotherapy. Plieth notes that the Mystic trial was primarily a bust. The trial failed its PFS and OS primary endpoints for the Imfinzi plus tremlimumab combo in subjects with PD-L1 at 25 percent or above, representing 48 of the 1,118 total enrolled.
AstraZeneca apparently claims better results if the data care cut by patients’ tumor mutational burden (TMB), a controversial market earlier touted by Bristol-Myers Squibb. Consequently, AstraZeneca will use the Mystic data-dredge to refocus another trail, Nepture on TMB to try and verify the benefit prospectively. The Evaluate writer reports that “the elephant in the room is the ready availability of Merck’s Keytruda plus chemo in all-comer NSCLC patients.